KP Biomedical Engineering - Issue #15

-Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program NATICK, Mass.--(BUSINESS WIRE)

--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass.

-U.S.-Based Remote Robotic-Assisted Surgery Demonstration Successfully Completed Through Collaborations with Virtual Incision, Sovato, City of Hope, and the University of Illinois Chicago LINCOLN, Neb.--(BUSINESS WIRE)

--Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), the world’s first miniaturized robotic-assisted surgery (RAS) device, and Sovato Health, the world’s only comprehensive solution designed to enable remote surgery and procedure programs, announced the successful completion of a preclinical demonstration of nearly 40,000 miles combined distance.

-Arlington Capital Partners Acquires TEAM Technologies WASHINGTON--(BUSINESS WIRE)

--Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, announced it has acquired TEAM Technologies, Inc (“TEAM Tech”), a leading global manufacturer of essential healthcare products, from Clearlake Capital Group (“Clearlake”). TEAM Tech is a leading provider of specialized manufacturing and strategic supply chain solutions to blue-chip healthcare customers.

-Natera Issues Statement on Guardant Health Litigation AUSTIN, Texas--(BUSINESS WIRE)

--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant’s Reveal test. Today, a jury issued a decision in Guardant’s favor. We disagree with this decision and will ask the Court to overturn it.

-Viromed Medical AG: Cold Plasma as a Digital Antibiotic for the Lungs PINNEBERG, Germany--(BUSINESS WIRE)

--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for approval as a therapy.

-Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study BERLIN--(BUSINESS WIRE)

--Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies.

-Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs CAMBRIDGE, Mass.--(BUSINESS WIRE)

--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs.

-88% of Type 2 Diabetics Would Take Glucose Readings More Consistently Knowing Their Doctor Is “Watching” TAMPA, Fla.--(BUSINESS WIRE)

--The results of the 2024 National Diabetes Care Survey, a longitudinal analysis of patients with Type 2 diabetes in the United States, have been tabulated and offer vital insights into how cellular remote patient monitoring (RPM)™ can make a difference in diabetes management. The survey results show that patients, more than ever, would test their glucose more regularly if their reading was sent to their provider, and that number increased 34.8% year-over-year.

-GE HealthCare unveils Pristina Via to streamline technologist workflow and improve patient-centered breast care CHICAGO--(BUSINESS WIRE)

--GE HealthCare announced the new Pristina Via™* mammography system designed to enhance the screening experience for both technologists and patients. Debuting at the Radiological Society of North America’s 2024 Annual Meeting, this innovation provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care.

-GE HealthCare Unveils Sonic DL for 3D, Expanding Deep Learning Innovations in MRI CHICAGO--(BUSINESS WIRE)

--GE HealthCare (Nasdaq: GEHC) unveiled Sonic DL for 3Dii, the newest addition to its effortless imaging portfolio, designed to accelerate MRI scans across a wide range of clinical applications. Sonic DL for 3D builds on GE HealthCare’s deep learning innovation legacy and the success of AIR Recon DL, which has helped over 34 million patients to date.

-Varex Introduces LUMEN HD and LUMEN HD Pro: Radiography Detectors Built for the New Demands in Imaging SALT LAKE CITY--(BUSINESS WIRE)

--Varex Imaging Corporation (Nasdaq: VREX) is proud to introduce the LUMEN HD and LUMEN HD Pro digital radiography detectors, designed to meet the evolving standards of healthcare imaging. As the demands of medical imaging continue to shift, these detectors are built to offer reliable, fast, and user-friendly performance in today’s cost-conscious environment. Key Features and Benefits: Reliable.

-Detection Technology launches advanced X-ray detector portfolio at RSNA 2024

--Detection Technology, a global leader in X-ray detector solutions, unveils a comprehensive portfolio of flat panel X-ray detectors at the RSNA 2024 exhibition to advance medical imaging.

-Groundbreaking method profiles gene activity in the living brain

--A groundbreaking method to profile gene activity in the living human brain has been developed by researchers at FutureNeuro, the Research Ireland Centre for Translational Brain Science and RCSI University of Medicine and Health Sciences, in collaboration with international partners.

-Ultromics obtains FDA clearance for Cardiac Amyloidosis screening device

--Ultromics' EchoGo Amyloidosis, clinical AI for echocardiography with the potential to revolutionise early detection of Cardiac Amyloidosis according to the company, has received US Food and Drug Administration (FDA) clearance.

-CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform

--CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy, and Tomocube, a leader in holotomography (HT) technology, today announced a strategic collaboration to provide a next-generation multimodal imaging platform, the HT-X1™ Plus

-Wearable electrical nerve stimulation device can reduce pain and fatigue linked to long COVID

--A wearable electrical nerve stimulation device can provide relief to people experiencing the persistent pain and fatigue linked to long COVID, a study co-led by UCLA and Baylor College of Medicine researchers suggests.

-VUZE Medical demonstrates new multi-tool 3D guidance in spine surgery

--VUZE Medical, a privately-held company aiming to transform intra-operative guidance in spinal interventions currently aided only by 2D X-ray, has recently demonstrated concurrent software-based 3D guidance of dual-sided vertebral insertions.

-Emory University Hospital performs first U.S. implant of novel ventricular assist device

--On Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ventricular assist device (VAD), which provides crucial care to patients with failing hearts.

-McMaster University develops fast and easy test for bacteria detection in fluids

--A novel new test for bacteria in fluids makes it as easy as observing a color change to confirm the presence of disease-causing pathogens, promising much easier diagnostic tests and greater food safety.

-AI models beat human experts in forecasting neuroscience study results

--Large language models, a type of AI that analyses text, can predict the results of proposed neuroscience studies more accurately than human experts, finds a new study led by UCL (University College London) researchers.

-UK medical device companies to benefit from landmark agreement with Medical Alley in the US

--Medilink UK, a professional membership association and specialist consultancy for the life sciences sector, has signed an agreement with Medical Alley to support medical device companies in the UK.

-DNA-based nanorobotic hand could block viruses and enable rapid diagnostics

--A tiny, four-fingered "hand" folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, University of Illinois Urbana-Champaign researchers report.

-New guidelines for safely integrating ai into clinical settings

--As artificial intelligence (AI) becomes more prevalent in health care, organizations and clinicians must take steps to ensure its safe implementation and use in real-world clinical settings, according to an article co-written by Dean Sittig, PhD, professor with McWilliams School of Biomedical Informatics at UTHealth Houston and Hardeep Singh, MD, MPH, professor at Baylor College of Medicine.

-New dropletronic devices could transform bioengineering and medicine

--Oxford University researchers have made a significant step towards realizing a form of 'biological electricity' that could be used in a variety of bioengineering and biomedical applications, including communication with living human cells.